TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17943084

Group type: EXPERIMENTAL
Intervention: Urotensin II (UTN)
Number of subjects: 122
Study: 17951527

Group type: EXPERIMENTAL
Intervention: Deferasirox at 20 mg/kg per day
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Deferasirox at 30 mg/kg per day
Number of subjects: 541

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Splenectomized patients
Number of subjects: 541
Study: 17954810

Group type: EXPERIMENTAL
Intervention: homocysteine level lowering therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17957238

Group type: EXPERIMENTAL
Intervention: MVA85A administered four weeks after BCG vaccination (short interval)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG vaccination alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: MVA85A administered many years after BCG vaccination (long interval)
Number of subjects: 0
Study: 17959415

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 52
Study: 17959855

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) at 0.15 mg/kg per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) at 0.2 mg/kg per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 24
Study: 17959863

Group type: EXPERIMENTAL
Intervention: Bloodletting intervention for 2 years
Number of subjects: 17
Study: 17962585

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study: 17973983

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 200
Study: 17975162

Group type: EXPERIMENTAL
Intervention: Defucosylated anti-CCR4 monoclonal antibody KM2760
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defucosylated anti-CCR4 monoclonal antibody KM2760 combined with immunomodulatory cytokines (interleukin-12, IFN-alpha-2b, IFN-gamma)
Number of subjects: 0
Study: 17981652

Group type: EXPERIMENTAL
Intervention: Nelfinavir monotherapy, 1250 mg orally, BID for 3 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 15
Study: 17981912

Group type: EXPERIMENTAL
Intervention: PAVM embolisation
Number of subjects: 323
Study: 17984237

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR 20 mg/q28d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR 30 mg/q28d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR 40 mg/q28d
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control of GH and IGF-I levels
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Glucose tolerance
Number of subjects: 56
Study: 17989313

Group type: EXPERIMENTAL
Intervention: BiRD (Biaxin [clarithromycin] 500 mg orally twice daily, lenalidomide [Revlimid] 25 mg orally daily on days 1 to 21, dexamethasone 40 mg orally once weekly)
Number of subjects: 72
Study: 17990139

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17990291

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) in polio survivors
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) in healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fatiguing exercise in polio survivors
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Twitch interpolation in polio survivors
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Assessment of motor cortex excitability in polio survivors
Number of subjects: 24

Group type: COMPARATOR
Intervention: Assessment of motor cortex excitability in healthy controls
Number of subjects: 24
Study: 17996820

Group type: EXPERIMENTAL
Intervention: Beta-blockers at hospital discharge
Number of subjects: 20118

Group type: COMPARATOR
Intervention: No beta-blockers at hospital discharge
Number of subjects: 20118
Study: 17999759

Group type: EXPERIMENTAL
Intervention: Twice weekly dosing of epoetin delta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once weekly dosing of epoetin delta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin delta (all patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 0
Study: 18000186

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study: 18003886

Group type: EXPERIMENTAL
Intervention: Ofatumumab 100 mg (1 dose) + 500 mg (3 doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg (1 dose) + 1000 mg (3 doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg (1 dose) + 2000 mg (3 doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ofatumumab (all cohorts)
Number of subjects: 33
Study: 18005455

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 1.5 atm and 100% oxygen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 1.3 atm and 24% oxygen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Parental observations of children post-HBOT
Number of subjects: 18
Study: 18008060

Group type: EXPERIMENTAL
Intervention: GCKR rs780094 A-allele
Number of subjects: 16853
Study: 18021411

Group type: EXPERIMENTAL
Intervention: Lifestyle Goals
Number of subjects: 35

Group type: COMPARATOR
Intervention: Structured Goals
Number of subjects: 35
Study: 18021418

Group type: EXPERIMENTAL
Intervention: Operative gamma camera
Number of subjects: 1
Study: 18021496

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 400-800 mg from day 4 to 84)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 477
Study: 18024436

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening interpretation by 16 radiologists
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Follow-up recommendations for positive cases
Number of subjects: 135
Study: 18025537

Group type: EXPERIMENTAL
Intervention: Trandolapril therapy
Number of subjects: 2977

Group type: EXPERIMENTAL
Intervention: Higher ACR (even within normal range)
Number of subjects: 2977

Group type: EXPERIMENTAL
Intervention: Increase in ACR over time
Number of subjects: 2977
Study: 18025796

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 165

Group type: COMPARATOR
Intervention: Caesarean section
Number of subjects: 165
Study: 18026714

Group type: EXPERIMENTAL
Intervention: Oral taurine (TAU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (NAC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intralipid and heparin (IH) infusion
Number of subjects: 9
Study: 18031749

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Definitions of MS by Viner
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Definitions of MS by Weiss
Number of subjects: 264

Group type: COMPARATOR
Intervention: Other proposed definitions of MS
Number of subjects: 264
Study: 18034602

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional methods (self-monitored blood glucose, SMBG)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CGMS
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CGMS and SMBG
Number of subjects: 125
Study: 18039368

Group type: COMPARATOR
Intervention: Ex-smokers with COPD
Number of subjects: 114

Group type: COMPARATOR
Intervention: Long-term quitters (> or =3.5 years)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 114
Study: 18039992

Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study: 18042798

Group type: EXPERIMENTAL
Intervention: Etanercept plus steroids
Number of subjects: 160

Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Etanercept plus steroids (related donors)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Steroids alone (related donors)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Etanercept plus steroids (unrelated donors)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Steroids alone (unrelated donors)
Number of subjects: 160
Study: 18043905

Group type: COMPARATOR
Intervention: HbA1c 5.19-5.59% (top quintile)
Number of subjects: 27210

Group type: COMPARATOR
Intervention: HbA1c 5.60-5.99%
Number of subjects: 27210

Group type: EXPERIMENTAL
Intervention: HbA1c range 4.50-7.00%
Number of subjects: 27210

Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 27210
Study: 18045470

Group type: EXPERIMENTAL
Intervention: Contrast enhanced Breast MRI
Number of subjects: 500
Study: 18048643

Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice daily)
Number of subjects: 119
Study: 18050221

Group type: EXPERIMENTAL
Intervention: Rituximab (2 infusions of 1,000 mg given 2 weeks apart)
Number of subjects: 1039
Study: 18053191

Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with celecoxib (escalating doses of bortezomib on a weekly or twice-weekly schedule and celecoxib 200 mg to 400 mg twice daily)
Number of subjects: 18
Study: 18053199

Group type: EXPERIMENTAL
Intervention: Chlamydia screening and treatment for those found to be infected
Number of subjects: 2526

Group type: COMPARATOR
Intervention: Non-participants (control group)
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: Participants contacted post-recruitment
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: Participants regarding consequences of untreated chlamydia
Number of subjects: 2526
Study: 18054555

Group type: EXPERIMENTAL
Intervention: GB virus C (GBV-C) RNA positive patients
Number of subjects: 158

Group type: COMPARATOR
Intervention: GB virus C (GBV-C) RNA negative patients
Number of subjects: 158
Study: 18054887

Group type: EXPERIMENTAL
Intervention: Intravenous bevacizumab (5 mg/kg)
Number of subjects: 10
Study: 18055730

Group type: EXPERIMENTAL
Intervention: Spinal analgesia (7.5 mg bupivacaine)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Complete breech presentation before external cephalic version
Number of subjects: 70
Study: 18055865

Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg every 7 +/- 2 days for 4 weeks; 900 mg 7 +/- 2 days later; followed by 900 mg every 14 +/- 2 days for a total treatment period of 52 weeks)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 97
Study: 18056840

Group type: EXPERIMENTAL
Intervention: Presence of multilineage dysplasia (MLD) in 1332 individuals receiving intensive AML therapy
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of MLD presence
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: MLD association with unfavorable cytogenetic profile
Number of subjects: 1766
Study: 18068035

Group type: EXPERIMENTAL
Intervention: Assessment at 10 to 14 weeks after MI
Number of subjects: 322

Group type: COMPARATOR
Intervention: Assessment at 2 to 4 weeks after MI
Number of subjects: 322
Study: 18070995

Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-based antihypertensive therapy
Number of subjects: 0
Study: 18071030

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a plus oral doxycycline (100 mg daily for 4 months)
Number of subjects: 15
Study: 18071034

Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pergolide treatment (meta-analysis)
Number of subjects: 96
Study: 18074068

Group type: EXPERIMENTAL
Intervention: Prolift transvaginal mesh repair
Number of subjects: 123
Study: 18077791

Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 249
Study: 18078870

Group type: EXPERIMENTAL
Intervention: Plant sterols (1.0 g/1000 kcal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No plant sterols
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 42
Study: 18079362

Group type: EXPERIMENTAL
Intervention: SGN-30 (4 dose levels: 2, 4, 8, or 12 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SGN-30 (6 weekly doses)
Number of subjects: 24
Study: 18081737

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin
Number of subjects: 57

Group type: COMPARATOR
Intervention: standard interferon/ribavirin
Number of subjects: 57

Group type: COMPARATOR
Intervention: peginterferon alfa-2b/ribavirin
Number of subjects: 57
Study: 18082486

Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel and acetylsalicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral anticoagulant
Number of subjects: 0
Study: 18083847

Group type: EXPERIMENTAL
Intervention: Caspase-dependent cytochrome c-related activation of caspase-3 (CRAC(dep)) positive patients (intact signaling)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CRAC(dep) negative patients (deficient signaling)
Number of subjects: 45
Study: 18084623

Group type: EXPERIMENTAL
Intervention: IV bolus injection of ferumoxytol (carboxymethyl dextran-based magnetic nanoparticle)
Number of subjects: 10
Study: 18084743

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Bupropion (sustained release) 150 mg BID
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study: 18089335

Group type: EXPERIMENTAL
Intervention: Caspofungin (50 to 100 mg/day) for invasive candidiasis (IC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caspofungin (50 to 100 mg/day) for invasive aspergillosis (IA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caspofungin (50 to 100 mg/day)
Number of subjects: 22
Study: 18089985

Group type: EXPERIMENTAL
Intervention: INSPIRE intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study: 18089990

Group type: EXPERIMENTAL
Intervention: Behavioral intervention trial (2001-2005)
Number of subjects: 1126
Study: 18090358

Group type: EXPERIMENTAL
Intervention: Estradiol levels
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Estradiol quartiles
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Estradiol level of 100 pg/mL
Number of subjects: 301
Study: 18090508

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day for 3 weeks after a 1-week titration at 10 mg/day, then increased to a maximum of 50 mg/day for 12 weeks if needed)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Escitalopram (high-dose, mean dose 33.8 mg/day at endpoint)
Number of subjects: 67
Study: 18091520

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 728
Study: 18093207

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 1855
Study: 18096059

Group type: EXPERIMENTAL
Intervention: Vinorelbine (20 mg/m2) and topotecan (escalating doses of 2, 2.5, 3, 3.5, and 4 mg/m2) administered on days 1 and 8 every 21 days
Number of subjects: 18
Study: 18155707

Group type: EXPERIMENTAL
Intervention: Substitution of aspartic acid to nonaspartic acid at residue 57 of DQbeta1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonaspartic acid homozygosity at DQbeta1 57
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonaspartic acid heterozygosity at DQbeta1 57
Number of subjects: 40
Study: 18162025

Group type: EXPERIMENTAL
Intervention: Family history of substance use disorder (SUD)
Number of subjects: 4010

Group type: COMPARATOR
Intervention: No family history of substance use disorder (SUD)
Number of subjects: 4010
Study: 18163417

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 6610
Study: 18163506

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIGs) administered at 0.5 gm/kg/day for 4 days, as additional therapy administered monthly for 6 months.
Number of subjects: 22
Study: 18165388

Group type: EXPERIMENTAL
Intervention: Intracervical balloon placement
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intrauterine balloon placement
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 69
Study: 18166563

Group type: EXPERIMENTAL
Intervention: Methadone maintenance (50-105 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 16
Study: 18174826

Group type: EXPERIMENTAL
Intervention: DAT1 genotype
Number of subjects: 29

Group type: COMPARATOR
Intervention: Stimulant medication (implied as a comparison)
Number of subjects: 29
Study: 18178411

Group type: EXPERIMENTAL
Intervention: Low hemoglobin (<12.1 g/dl)
Number of subjects: 48612

Group type: COMPARATOR
Intervention: High hemoglobin (highest quartile)
Number of subjects: 48612
Study: 18178412

Group type: EXPERIMENTAL
Intervention: BNP >or=840 pg/ml and Tn increased
Number of subjects: 77467

Group type: COMPARATOR
Intervention: BNP <840 pg/ml and Tn not increased
Number of subjects: 77467
Study: 18182574

Group type: EXPERIMENTAL
Intervention: Cytarabine (0.5-1.5 mg/kg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: ML-DS with history of TL
Number of subjects: 146

Group type: COMPARATOR
Intervention: ML-DS without documented TL
Number of subjects: 146
Study: 18184959

Group type: EXPERIMENTAL
Intervention: Sirolimus therapy for 12 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sirolimus therapy for 12 months (in patients with lymphangioleiomyomatosis)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1 year after sirolimus therapy was discontinued
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sirolimus therapy
Number of subjects: 25
Study: 18190252

Group type: EXPERIMENTAL
Intervention: WNV DNA vaccine (3 doses)
Number of subjects: 15
Study: 18191528

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT) followed by resection
Number of subjects: 302

Group type: COMPARATOR
Intervention: Primary resection without any pretreatment
Number of subjects: 302

Group type: COMPARATOR
Intervention: Patients with unresectable tumours
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 302
Study: 18194527

Group type: EXPERIMENTAL
Intervention: Intervention 1 targeting self-efficacy; involved a graded task and action plan development.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 2 targeting anticipated consequences; involved persuasive communication with visual aids.
Number of subjects: 0
Study: 18195175

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 127

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 127
Study: 18195220

Group type: EXPERIMENTAL
Intervention: Iodine 125 plaques
Number of subjects: 162
Study: 18201682

Group type: EXPERIMENTAL
Intervention: Conjunctival resection combined with Tenon layer excision
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (20 patients undergoing cataract and retinal surgery)
Number of subjects: 30
Study: 18206507

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg, 2 intravenous applications, 2 weeks apart)
Number of subjects: 6
Study: 18206856

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) augmentation treatment for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal control subjects (no treatment)
Number of subjects: 19
Study: 18212631

Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR) monotherapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sirolimus plus Tacrolimus (SIR-TAC) combination therapy
Number of subjects: 5
Study: 18213379

Group type: EXPERIMENTAL
Intervention: SP+1AS
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: SP+3AS
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: 3AQ+3AS
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: SP+3AQ
Number of subjects: 2102
Study: 18215105

Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 14
Study: 18216052

Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Smoking control subjects
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Nonsmoking control subjects
Number of subjects: 2180
Study: 18218852

Group type: EXPERIMENTAL
Intervention: Gene therapy with retrovirally transduced hematopoietic stem/progenitor cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to 2'-deoxy-adenosine
Number of subjects: 0
Study: 18221516

Group type: EXPERIMENTAL
Intervention: Collaborative stepped care intervention
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Enhanced usual care control intervention
Number of subjects: 3600
Study: 18221542

Group type: EXPERIMENTAL
Intervention: DC/Apo-Nec vaccine (dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DC/Apo-Nec vaccine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IL-10 promoter -1082 polymorphism analysis
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Follow-up of patients post-surgery
Number of subjects: 16
Study: 18222230

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with cisplatin and etoposide, concurrent radiation
Number of subjects: 10
Study: 18222352

Group type: EXPERIMENTAL
Intervention: Carotid artery stent (CAS) placement with Carotid WALLSTENT plus FilterWire EX/EZ Emboli Protection System
Number of subjects: 480
Study: 18231580

Group type: EXPERIMENTAL
Intervention: PEV3A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 18235052

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 supplementation (1,000 mg elemental calcium plus 400 IU of vitamin D3 daily)
Number of subjects: 33951

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33951
Study: 18237873

Group type: EXPERIMENTAL
Intervention: Peginterferon with ribavirin therapy
Number of subjects: 588

Group type: COMPARATOR
Intervention: Null response
Number of subjects: 588
Study: 18249033

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 247

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Early decrease in CA 19-9 concentration of at least 50% after two cycles of chemotherapy
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Decrease in CA 19-9 concentration of at least 50% at nadir
Number of subjects: 247